Literature DB >> 29571019

Involvement of estrogen receptors in silibinin protection of pancreatic β-cells from TNFα- or IL-1β-induced cytotoxicity.

Jing Yang1, Yue Sun1, Fanxing Xu1, Weiwei Liu1, Toshihiko Hayashi1, Satoshi Onodera2, Shin-Ichi Tashiro3, Takashi Ikejima4.   

Abstract

Silibinin is a polyphenolic flavonoid that exhibits anticarcinogenic, anti-inflammatory and cytoprotective effects. The effect of silibinin on pancreatic islet β-cell is yet largely unknown in spite of well documented-hepatoprotective effects. Protecting the functional insulin-producing β-cells in the pancreas is a major therapeutic challenge in the patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). This study reports the effect of silibinin on the rat pancreatic β-cell line, INS-1, damaged with pro-inflammatory cytokine, TNFα or IL-1β. Exposure to TNFα or IL-1β for 48 h caused INS-1 cells to reduce the production of insulin as well as cell viability. These actions of TNFα or IL-1β are associated with suppression of the expression of estrogen receptors (ERs). Further study revealed that silibinin protected the suppression in the expression of both ERα and ERβ that were involved in insulin synthesis and release, respectively. Furthermore, evidence is obtained that silibinin may impede the loss of critical INS-1 cells by promoting autophagy and preventing apoptosis. Direct cytoprotective effects of silibinin on INS-1 cells suggest that silibinin may be therapeutically beneficial for diabetes.
Copyright © 2018. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Estrogen receptors (ERs); IL-1β; Silibinin; TNFα

Mesh:

Substances:

Year:  2018        PMID: 29571019     DOI: 10.1016/j.biopha.2018.01.128

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block.

Authors:  Nikolaos P E Kadoglou; Chrystalla Panayiotou; Michail Vardas; Nikolaos Balaskas; Nikolaos G Kostomitsopoulos; Alexandra K Tsaroucha; Georgia Valsami
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

2.  Silibinin relieves UVB-induced apoptosis of human skin cells by inhibiting the YAP-p73 pathway.

Authors:  Wei-Wei Liu; Fang Wang; Can Li; Xiao-Yu Song; Wuxiyar Otkur; Yu-Ying Zhu; Toshihiko Hayashi; Kazunori Mizuno; Shunji Hattori; Hitomi Fujisaki; Takashi Ikejima
Journal:  Acta Pharmacol Sin       Date:  2021-12-15       Impact factor: 7.169

3.  The association of calcium channel blockers with β-cell function in type 2 diabetic patients: A cross-sectional study.

Authors:  Dong Zhao; Yu Cao; Cai-Guo Yu; Sha-Sha Yuan; Ning Zhang; Yuan-Yuan Zhang; Jan A Staessen; Ying-Mei Feng
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-03-22       Impact factor: 3.738

4.  Oral Administration of Bacterial β Cell Expansion Factor A (BefA) Alleviates Diabetes in Mice with Type 1 and Type 2 Diabetes.

Authors:  Huan Wang; Jing Wei; Hong Hu; Fuyin Le; Heng Wu; Hong Wei; Jie Luo; Tingtao Chen
Journal:  Oxid Med Cell Longev       Date:  2022-02-10       Impact factor: 6.543

5.  Discovery of Potent Glucokinase and PPARγ Dual-Target Agonists through an Innovative Scheme for Regioselective Modification of Silybin.

Authors:  Zhipeng Zhang; Yanqiu Meng; Zhan Wang; Yu Mei; Shite Gao; Yuejiao Wu; Shuxian Du
Journal:  ACS Omega       Date:  2022-01-20

Review 6.  Mechanistic Insights into the Pharmacological Significance of Silymarin.

Authors:  Karan Wadhwa; Rakesh Pahwa; Manish Kumar; Shobhit Kumar; Prabodh Chander Sharma; Govind Singh; Ravinder Verma; Vineet Mittal; Inderbir Singh; Deepak Kaushik; Philippe Jeandet
Journal:  Molecules       Date:  2022-08-21       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.